Evogene Ltd.
EVGNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Lake Street | maintain | Buy | May 22, 2025 |
| Lake Street | maintain | Buy | Aug 23, 2024 |
| Lake Street | maintain | Buy | Aug 18, 2023 |
| Roth MKM | maintain | Buy | Jul 21, 2023 |
| Aegis Capital | maintain | Buy | Sep 12, 2022 |
| Roth MKM | maintain | Buy | Sep 2, 2022 |
| Credit Suisse | maintain | Outperform | Nov 12, 2014 |
Earnings History
Next report: Nov 19, 2026 · EPS est. $-0.19| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 18, 2026 | $-0.13 | $-0.27 | $347.0K | $325.0K |
| May 20, 2026 | $-0.60 | $-0.27 | $334.0K | $350.0K |
| Mar 5, 2026 | $-0.61 | $-0.26 | $314.0K | $275.0K |
| Nov 20, 2025 | $-0.31 | $-0.26 | $312.0K | $275.0K |
| Aug 19, 2025 | $-0.62 | $-0.63 | $884.0K | $930.0K |
| May 21, 2025 | $-0.38 | $-0.63 | $2.4M | $1.9M |
| Mar 6, 2025 | $0.06 | $-0.72 | $1.6M | $5.0M |
| Nov 21, 2024 | $-1.31 | $-1.01 | $1.7M | $3.6M |
News
Zoom conference call scheduled for November 19, 2026, 9:00 AM ET REHOVOT, Israel, Nov. 5, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the third quarter 2026, on Thursday , November 19, 2026.
Advancing a First-in-Class Small-Molecule Therapeutic, Guided by World-Leading Experts, to Address a Multi-Billion-Dollar Unmet Need in Steroid-Refractory Patients REHOVOT, Israel, Oct. 28, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in AI-driven generative design of small molecules for the pharmaceutical and agricultural industries, today announced acute graft-versus-host disease (aGVHD) as the target indication for it…
Company to Attend BIO-Europe in Cologne, Germany, and Present a Scientific Poster at Drug Discovery Chemistry Europe in Barcelona, Spain REHOVOT, Israel, Oct. 26, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced its participation in two upcoming industry conferences in Europe: BIO-Europe, to be held November …
The roadshow will connect leading Israeli AI-driven drug discovery and biotechnology companies with U.S. investors, pharmaceutical companies, and potential strategic partners REHOVOT, Israel, Oct. 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in AI-driven generative design of small molecules for pharmaceutical and agricultural applications, today announced its participation in the AI Drug Discovery Roadshow, taking pl…
REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it has entered into a comprehensive cooperation agreement (the "Agreement") with L.I.A.
Evogene (NASDAQ: EVGN - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Institutional and Insider Ownership 10.4% of Evogene shares
REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- Evogene Ltd.
Vancouver, British Columbia--(Newsfile Corp. - September 14, 2026) - EverGen Infrastructure Corp. (TSXV: EVGN) (OTCQB: EVGIF) is pleased to announce its participation in the upcoming 3 rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel. Chase Edgelow, Co-founder & Chief Executive Office of EverGen, will participate as a Featured Company and will hold one-on-one meetings with interested investors and capital markets prof…
Evogene Ltd. (NASDAQ: EVGN - Get Free Report) was the target of a large drop in short interest in August. As of August 31st, there was short interest totaling 53,001 shares, a drop of 77.2% from the August 15th total of 232,078 shares. Based on an average daily volume of 219,870 shares, the short-interest ratio is
Company urges shareholders to evaluate the significant changes already implemented and vote FOR all Evogene nominees on September 4, 2026, Annual General Meeting REHOVOT, Israel, Aug. 31, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today responded to the latest communication from dissident shareholders L.I.A.
EverGen Infrastructure Corp. (EVGN:CA) Q2 2026 Earnings Call Transcript
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQB: EVGIF), today reported financial results as at and for Q2 2026. All amounts are in Canadian dollars and are presented in thousands of dollars unless otherwise stated and have been prepared in accordance with IFRS. Financial Highlights The following table presents EverGen's Consolidated Financial and Operating Summary: Three months ended June 30, 2026 June 30, 2025 $ C.
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN), is pleased to report the voting results from its Annual General Meeting of Shareholders (“AGM”) held on August 25, 2026. A total of 16,172,472 common shares were represented at the meeting, representing 62.43% of the Company's outstanding shares. The following is a summary of the proxy voting results for the AGM. 1. Election of Directors The following individuals were elected as.
EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Recommendations Reinforce Confidence in Evogene's Strategic Plan and Long-Term Value Creation Strategy Board Urges Shareholders to Vote FOR All Evogene Nominees, and to disregard the Pure Capital Nominees, at the September 4, 2026, Annual General Meeting REHOVOT, Israel, Aug. 25, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industrie…
Evogene Ltd. (EVGN) Q2 2026 Earnings Call Transcript
Company continues strategic transformation, initiated in 2025, into a focused, AI-driven computational chemistry company, with significant progress across pharmaceutical and agricultural product development programs Cash burn expected to decline to approximately $8.5–$9.5 million in 2026, compared with approximately $14.4 million in 2025 and approximately $20.5 million in 2024 Second-quarter net loss was reduced to approximately $1.8 million, compared with approximately $4.7 million in the seco…
Zoom conference call scheduled for August 18, 2026, at 9:00 AM ET REHOVOT, Israel, Aug. 14, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that its Chairman, Nir Nimrodi, will join the Company's upcoming quarterly results conference call on August 18, 2026.